Bemotrizinol FDA Approval: The First New US Sunscreen Filter in 25 Years and What It Means for Pigmentation Prevention (2026 Industry Analysis)

For the first time since the Clinton administration, the United States has a genuinely new sunscreen active ingredient. In June 2026 the U.S. Food and Drug Administration added bemotrizinol — INCI name bis-ethylhexyloxyphenol methoxyphenyl triazine, better known commercially as Tinosorb S or Parsol Shield — to the list of permitted active ingredients for over-the-counter sunscreens. Products containing it become eligible for the U.S. market from 9 August 2026, with the sponsor, dsm-firmenich, holding an 18-month period of marketing exclusivity before other suppliers can follow.

For pigmentation science this is not a footnote. Bemotrizinol is one of the most spectrally efficient broad-spectrum absorbers available, and the long-wavelength UVA region it covers is the band most strongly implicated in melasma persistence and post-inflammatory hyperpigmentation. The bemotrizinol FDA approval closes a gap that quietly limited how well American formulations could protect melanin-rich skin.

What the FDA Actually Approved — and Why It Took 25 Years

The U.S. regulates sunscreens as OTC drugs under a monograph system, not as cosmetics — one structural decision that explains the stagnation. The last filter cleared for general monograph use dates to the late 1990s; ecamsule reached the market in 2006 only through a product-specific New Drug Application. The European Union, by contrast, operates roughly 30 approved filters under Annex VI of its Cosmetic Regulation, and the ASEAN Cosmetic Directive mirrors that list almost entirely.

The timeline is instructive for anyone tracking regulatory risk:

• 2000: Bemotrizinol approved in the EU at up to 10%. Australia, Japan and ASEAN follow.
• 2019: The sponsor agrees a study plan with FDA to support a GRASE (generally recognised as safe and effective) determination.
• 2020–2024: Maximal-usage trial and toxicology package generated under the CARES Act pathway, which replaced rulemaking with an administrative order process.
• December 2025: Proposed order issued.
• June 2026: Final order issued — roughly seven months later, an unusually fast turnaround.

The speed matters as much as the ingredient: it proves the CARES Act order pathway can move. Filters with decades of EU safety history — bisoctrizole, iscotrizinol, drometrizole trisiloxane — now have a precedent.

The Molecular Case: Spectral Coverage and Photostability

Absorption Profile

Bemotrizinol is a symmetric triazine with two absorption maxima, near 310 nm and 340 nm. That dual-peak profile means one molecule covers UVB, UVA II and much of UVA I — the 340–400 nm band reaching the dermal–epidermal junction where melanocytes sit. Its molar extinction coefficient is among the highest of any organic filter in use, so target SPF and UVA-PF values are reachable at lower active load, leaving room for texture, antioxidants and brightening actives.

Its molecular weight of approximately 628 Da matters too. Percutaneous absorption drops sharply above roughly 500 Da — the pharmacokinetic argument separating bemotrizinol from the small-molecule filters behind the 2019–2020 systemic absorption debate, in which avobenzone, oxybenzone and octocrylene all exceeded the 0.5 ng/mL plasma threshold triggering further safety assessment (Matta MK et al., JAMA. 2020;323(3):256–267).

Photostability — the Avobenzone Fix

The most practically useful property is stabilisation. Avobenzone, still the primary UVA I absorber in most American products, degrades substantially under irradiation, losing a large fraction of its absorbance within a single MED-equivalent exposure. Bemotrizinol acts as an excited-state quencher: co-formulation photostabilises both avobenzone and ethylhexyl methoxycinnamate, preserving absorbance across sustained irradiation (Chatelain E, Gabard B. Photochem Photobiol. 2001;74(3):401–406).

U.S. developers have spent two decades building UVA protection on a filter that partially destroys itself in sunlight, using octocrylene as a workaround. That constraint is now optional.

Clinical Evidence: The Pigmentation Link

The reason this belongs in a pigmentation conversation rather than a general sun-care one comes down to action spectrum data.

• Long-wavelength UVA and visible light induce pigmentation in melanocompetent skin. Mahmoud BH et al. found visible light produced darker, more sustained pigmentation than UVA1 in Fitzpatrick IV–VI subjects, persisting up to two weeks (J Invest Dermatol. 2010;130(8):2092–2097).
• The effect is wavelength-specific. Duteil L et al. showed blue-violet light (~415 nm) generated markedly more pigmentation than red light at equivalent doses, with histological confirmation (Pigment Cell Melanoma Res. 2014;27(5):822–826).
• Broad-spectrum coverage changes melasma outcomes. In a double-blind randomised trial, patients using a sunscreen covering visible light plus UV achieved significantly greater MASI improvement than those on a UV-only product under identical depigmenting therapy (Castanedo-Cazares JP et al., Photodermatol Photoimmunol Photomed. 2014;30(1):35–42).
• Relapse prevention follows the same pattern. Boukari F et al. reported significantly fewer melasma relapses across a summer season with a sunscreen covering UV plus short-wavelength visible light versus UV alone (J Am Acad Dermatol. 2015;72(1):189–190.e1).

Bemotrizinol does not absorb visible light — no organic filter does, which is why iron oxides remain essential for melasma-focused products. What it does is raise the UVA I ceiling without pushing total active load to unworkable levels, freeing formulation budget for pigment-based visible-light coverage.

Market Consequences for 2026–2027

1. The exclusivity window creates a two-tier U.S. market. For 18 months, only products sourcing through the sponsor’s supply chain can carry bemotrizinol in the U.S. Expect premium high-SPF facial fluids and pigmentation-corrective ranges to lead, with mass adoption in 2028.

2. Cross-region formula convergence becomes possible. Brands selling into both North America and Southeast Asia have run separate sun-care systems because ASEAN registrations permit filters the U.S. did not — an expensive drag on dossiers, stability testing and inventory. A shared bemotrizinol backbone reduces it.

3. UVA claims get more competitive. The U.S. still lacks a mandatory graded UVA rating comparable to the EU’s UVA-PF ≥ SPF/3 rule or Japan’s PA system. Expect PA+++/PA++++ style communication to migrate into U.S. marketing — and regulatory attention to follow.

Formulation Implications When Pairing with Brightening Actives

Bemotrizinol is oil-soluble and crystallises readily, so the practical constraints are solubilisation and compatibility:

• Needs high-capacity polar emollients — C12-15 alkyl benzoate, dibutyl adipate, diisopropyl adipate — or a pre-dissolved dispersion grade to prevent recrystallisation on ageing.
• Stable across a wide pH range, so it tolerates both L-ascorbic acid systems and the near-neutral conditions preferred by niacinamide and tranexamic acid.
• Validate anionic emulsifiers and high electrolyte loads at 40 °C and under freeze–thaw; the filter is robust, the emollient package often is not.
• Confirm regional caps before finalising a global formula. EU and most ASEAN registrations permit up to 10%; the U.S. order sets its own maximum, and claims must be built against the lower of the two.

What to Watch Next

The immediate question is whether FDA applies the same pathway to the backlog. Bisoctrizole, the particulate partner filter to bemotrizinol, is the obvious next candidate. The second is whether visible-light protection ever acquires a regulatory definition: no jurisdiction has a standardised visible-light protection factor, so the ingredient most relevant to melasma — iron oxide — carries no claimable metric anywhere.

The takeaway for pigmentation-focused development is simple. The photoprotection layer of a brightening regimen has been the weakest link in U.S.-market formulations for two decades. As of August 2026, it no longer has to be.

References

1. U.S. FDA. Sunscreen: How to Help Protect Your Skin from the Sun. Updated June 2026.
2. Chatelain E, Gabard B. Photochem Photobiol. 2001;74(3):401–406.
3. Matta MK, Florian J, Zusterzeel R, et al. JAMA. 2020;323(3):256–267.
4. Mahmoud BH, Ruvolo E, Hexsel CL, et al. J Invest Dermatol. 2010;130(8):2092–2097.
5. Duteil L, Cardot-Leccia N, Queille-Roussel C, et al. Pigment Cell Melanoma Res. 2014;27(5):822–826.
6. Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, et al. Photodermatol Photoimmunol Photomed. 2014;30(1):35–42.
7. Boukari F, Jourdan E, Fontas E, et al. J Am Acad Dermatol. 2015;72(1):189–190.e1.
8. European Commission. Regulation (EC) No 1223/2009, Annex VI — UV filters allowed in cosmetic products.